Desazadesmethyldesferrithiocin
Alternative Names: DFTLatest Information Update: 24 Oct 2021
At a glance
- Originator GelTex Pharmaceuticals
- Class
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Iron overload
Most Recent Events
- 04 Apr 2003 No development reported - Preclinical for Iron overload in USA (PO)
- 21 Dec 2000 GelTex Pharmaceuticals has been acquired by Genzyme Corporation
- 22 Oct 1999 Preclinical development for Iron overload in USA (PO)